Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine and Cytarabine in AML and MDS
NCT00334074Phase 2Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Aug 2005
- Primary completion
- Feb 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Overall Response Rate (CR + PR) at 4 weeks. Started Aug 2005; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00334074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334074.